Rheumatoid arthritis and renal light-Chain deposition disease: Long-Term effectiveness of TNF-a blockade with etanercept

Research output: Contribution to journalArticlepeer-review

Abstract

A 68-year-old woman diagnosed with erosive rheumatoid arthritis (RA) was treated with intramuscular methotrexate 15 mg weekly and oral prednisone 5 mg daily. A favorable outcome of 6 years was followed by RA flare and nephrotic syndrome (NS). Renal biopsy revealed non-amyloid light-chain deposition disease. Laboratory analysis and bone marrow biopsy excluded monoclonal protein and plasma cell dyscrasia. Addition of subcutaneous etanercept, 25 mg twice weekly allowed rapid control of both arthritis and NS. To date, after over 7-year follow-up, RA is in clinical remission, 24-h albuminuria is consistently below 0.5 g, and serum creatinine is 0.9 mg/dl.

Original languageEnglish
Pages (from-to)909-912
Number of pages4
JournalInternational Urology and Nephrology
Volume43
Issue number3
DOIs
Publication statusPublished - Sep 2011

Keywords

  • Etanercept
  • Renal Light-Chain Deposition disease
  • Rheumatoid arthritis
  • TNF-blockade
  • Tumor Necrosis Factor-alpha (TNF-alpha)

ASJC Scopus subject areas

  • Nephrology
  • Urology

Fingerprint Dive into the research topics of 'Rheumatoid arthritis and renal light-Chain deposition disease: Long-Term effectiveness of TNF-a blockade with etanercept'. Together they form a unique fingerprint.

Cite this